[go: up one dir, main page]

MX2018014034A - Compuestos bicíclicos fusionados para el tratamiento de enfermedades. - Google Patents

Compuestos bicíclicos fusionados para el tratamiento de enfermedades.

Info

Publication number
MX2018014034A
MX2018014034A MX2018014034A MX2018014034A MX2018014034A MX 2018014034 A MX2018014034 A MX 2018014034A MX 2018014034 A MX2018014034 A MX 2018014034A MX 2018014034 A MX2018014034 A MX 2018014034A MX 2018014034 A MX2018014034 A MX 2018014034A
Authority
MX
Mexico
Prior art keywords
disease
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
MX2018014034A
Other languages
English (en)
Inventor
Anthony Pratt Benjamin
Mohan Raju
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of MX2018014034A publication Critical patent/MX2018014034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

En la presente se describen compuestos bicíclicos fusionados, composiciones y métodos para su uso en el tratamiento de enfermedades.
MX2018014034A 2016-05-25 2017-05-25 Compuestos bicíclicos fusionados para el tratamiento de enfermedades. MX2018014034A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341483P 2016-05-25 2016-05-25
US201662341486P 2016-05-25 2016-05-25
PCT/US2017/034493 WO2017205633A1 (en) 2016-05-25 2017-05-25 Fused bicyclic compounds for the treatment of disease

Publications (1)

Publication Number Publication Date
MX2018014034A true MX2018014034A (es) 2019-08-29

Family

ID=60411628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014034A MX2018014034A (es) 2016-05-25 2017-05-25 Compuestos bicíclicos fusionados para el tratamiento de enfermedades.

Country Status (13)

Country Link
US (1) US20200325140A1 (es)
EP (1) EP3463372A4 (es)
JP (1) JP2019520335A (es)
KR (1) KR20190040140A (es)
CN (1) CN109789149A (es)
AU (1) AU2017270203A1 (es)
BR (1) BR112018074231A2 (es)
CA (1) CA3025326A1 (es)
IL (1) IL263177A (es)
MX (1) MX2018014034A (es)
RU (1) RU2018145721A (es)
SG (2) SG11201810292YA (es)
WO (1) WO2017205633A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370480B (es) * 2014-11-21 2019-12-16 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
KR20220075381A (ko) 2019-10-01 2022-06-08 브리스톨-마이어스 스큅 컴퍼니 치환된 비시클릭 헤테로아릴 화합물
CN112402430A (zh) * 2020-12-11 2021-02-26 大连医科大学 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532235A (en) * 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
BRPI0412262A (pt) * 2003-07-23 2006-09-19 X Ceptor Therapeutics Inc derivados de azepina como agentes farmacêuticos
GB0513886D0 (en) * 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
EP2121621B1 (en) * 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090131409A1 (en) * 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
JP2012506848A (ja) * 2008-10-27 2012-03-22 グラクソ グループ リミテッド グルタミン酸受容体モジュレーターとしての三環式化合物
EP2935284A4 (en) * 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
WO2016151403A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease

Also Published As

Publication number Publication date
CA3025326A1 (en) 2017-11-30
AU2017270203A1 (en) 2019-01-03
IL263177A (en) 2018-12-31
WO2017205633A1 (en) 2017-11-30
SG11201810292YA (en) 2018-12-28
RU2018145721A (ru) 2020-06-25
SG10202011665SA (en) 2020-12-30
EP3463372A4 (en) 2019-11-13
KR20190040140A (ko) 2019-04-17
CN109789149A (zh) 2019-05-21
EP3463372A1 (en) 2019-04-10
BR112018074231A2 (pt) 2019-03-06
RU2018145721A3 (es) 2020-08-21
JP2019520335A (ja) 2019-07-18
US20200325140A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
ZA202107931B (en) Anti-tau antibodies and methods of use
IL264049A (en) Compounds, preparations and methods for treating the disease
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
IL264156A (en) Compounds, preparations and methods for treating the disease
PH12019501079A1 (en) Magl inhibitors
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MD20170032A2 (ro) Anticorpi anti-TIGIT
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
MX378739B (es) Compuestos de 2-oxindol.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
IL270927B (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2017008655A (es) Derivados de jasmonato y composiciones de los mismos.
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.